Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · see citing works

The consensus molecular subtypes of colorectal cancer

Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · see citing works

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · see citing works

Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study

Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · see citing works

Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079 · see citing works

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · see citing works

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487 · see citing works

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation

Gückenberger, M., Lievens, Y. N., Bouma, A. B., Collette, L., Dekker, A. L. A. J., deSouza, N. M., Dingemans, A. C., Fournier, B., Hurkmans, C., Lecouvet, F. E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30718-1 · Cited by 1,125 · see citing works

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005 · see citing works

Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164

Le, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02107 · Cited by 1,005 · see citing works

Mismatch Repair Status and <i>BRAF</i> Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772 · see citing works

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study

André, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4238 · Cited by 683 · see citing works

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

Schrock, A. B., Ouyang, C., Sandhu, J. S., Sokol, E. S., Jin, D. X., Ross, J. S., Miller, V. A., Lim, D. W., Amanam, I. U., Chao, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz134 · Cited by 620 · see citing works

Targeting the TGFβ pathway for cancer therapy

Neuzillet, C., Tijeras‐Raballand, A., Cohen, R., Cros, J. F., Faivre, S. J., Raymond, É., & Gramont, A. D. E. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.001 · Cited by 610 · see citing works

Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response

Mandal, R., Samstein, R. M., Lee, K.-W., Havel, J. J., Wang, H., Krishna, C., Sabio, E. Y., Makarov, V., Kuo, F., Blecua, P., et al. (2019) · Science · doi:10.1126/science.aau0447 · Cited by 549 · see citing works

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

Tazdait, M., Mezquita, L., Lahmar, J., Ferrara, R., Bidault, F., Ammari, S., Balleyguier, C., Planchard, D., Gazzah, A., Soria, J., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.017 · Cited by 349 · see citing works

Mutational Analysis of Patients with Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

Innocenti, F., Ou, F.-S., Qu, X., Zemla, T. J., Niedzwiecki, D., Tam, R., Mahajan, S., Goldberg, R. M., Bertagnolli, M. M., Blanke, C. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01798 · Cited by 317 · see citing works

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer

Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254 · see citing works

Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy

Maby, P., Tougeron, D., Hamieh, M., Mlecnik, B., Kora, H., Bindea, G., Angell, H. K., Fredriksen, T., Elie, N., Fauquembergue, É., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3051 · Cited by 250 · see citing works

Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status

Cohen, R., Hain, É., Buhard, O., Guilloux, A., Bardier–Dupas, A., Kaci, R., Bertheau, P., Renaud, F., Bibeau, F., Fléjou, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4942 · Cited by 248 · see citing works

BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression

Barras, D., Missiaglia, E., Wirapati, P., Sieber, O. M., Jorissen, R. N., Love, C., Molloy, P. L., Jones, I. T., McLaughlin, S., Gibbs, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0140 · Cited by 229 · see citing works

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies

Taı̈eb, J., Shi, Q., Pederson, L., Alberts, S. R., Wolmark, N., Cutsem, E. V., de Gramont, A., Kerr, R. S., Grothey, A. F., Lonardi, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz208 · Cited by 135 · see citing works

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors

Marisa, L., Svrcek, M., Collura, A., Becht, É., Cervera, P., Wanherdrick, K., Buhard, O., Goloudina, A. R., Jonchère, V., Sèlves, J., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx136 · Cited by 129 · see citing works

Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors

Sourrouille, I., Coulet, F., Lefèvre, J. H., Colas, C., Eyries, M., Svrcek, M., Bardier–Dupas, A., Parc, Y. R., & Soubrier, F. (2012) · Familial Cancer · doi:10.1007/s10689-012-9568-9 · Cited by 120 · see citing works

Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma

Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0086 · Cited by 117 · see citing works

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

Nishino, M., Ramaiya, N. H., Chambers, E. S., Adeni, A. E., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0193-2 · Cited by 115 · see citing works

Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

Morse, M. A., Overman, M. J., Hartman, L., Khoukaz, T., Brutcher, E., Lenz, H.-J., Atasoy, A., Shangguan, T., Zhao, H., & El-Rayes, B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0129 · Cited by 112 · see citing works

Majority of B2M -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High

Middha, S., Yaeger, R. D., Shia, J., Stadler, Z. K., King, S., Guercio, S., Paroder, V., Bates, ‬. D. B., Rana, S., Diaz, L. A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00321 · Cited by 111 · see citing works

Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes

Loupakis, F., Depetris, I., Biason, P., Intini, R., Prete, A. A., Leone, F., Lombardi, P., Filippi, R., Spallanzani, A., Cascinu, S., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0611 · Cited by 111 · see citing works

Programmed death-1 blockade in mismatch repair deficient colorectal cancer.

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Azad, N. S., Laheru, D. A., Donehower, R. C., Crocenzi, T. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.103 · Cited by 106 · see citing works

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Gul, A., Stewart, T. F., Mantia, C. M., Shah, N. J., Gatof, E. S., Long, Y., Allman, K. D., Ornstein, M. C., Hammers, H. J., McDermott, D. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03315 · Cited by 99 · see citing works

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

André, T., Berton, D., Curigliano, G., Ellard, S. L., Pérez, J. M. T., Arkenau, H., Abdeddaim, C., Moreno, V., Guo, W., Im, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.9 · Cited by 99 · see citing works

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency

Cohen, R., Buhard, O., Cervera, P., Hain, É., Dumont, S., Bardier–Dupas, A., Bachet, J., Gornet, J., López‐Trabada, D., Dumont, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.022 · Cited by 90 · see citing works

KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.

Le, D. T., Kavan, P., Kim, T. W., Burge, M., Cutsem, E. V., Hara, H., Boland, P. M., Laethem, J. V., Geva, R., Taniguchi, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3514 · Cited by 84 · see citing works

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

Cohen, R., Bennouna, J., Meurisse, A., Tournigand, C., de la Fouchardière, C., Tougeron, D., Borg, C., Mazard, T., Chibaudel, B., Garcia‐Larnicol, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001499 · Cited by 82 · see citing works

Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer

Ludford, K. T., Cohen, R., Svrcek, M., Foo, W. C., Colle, R., Parc, Y. R., Thomas, J. V., Morris, V. K., Kopetz, S., Chang, G. J., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa052 · Cited by 81 · see citing works

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

Tougeron, D., Sueur, B., Zaanan, A., de la Fouchardière, C., Sefrioui, D., Lecomte, T., Aparicio, T., Guetz, G. D., Artru, P., Hautefeuille, V., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32879 · Cited by 78 · see citing works

Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

Colle, R., Radzik, A., Cohen, R., Pellat, A., López‐Trabada, D., Cachanado, M., Duval, A., Svrcek, M., Menu, Y., & André, T. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.009 · Cited by 70 · see citing works

Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers

Diaz, L. A., Marabelle, A., Kim, T. W., Geva, R., Cutsem, E. V., André, T., Ascierto, P. A., Maio, M., Delord, J., Gottfried, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx367.020 · Cited by 65 · see citing works

KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer

Shiu, K.-K., Andre, T., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.6 · Cited by 59 · see citing works

Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.

Overman, M. J., Bergamo, F., McDermott, R., Aglietta, M., Chen, F., Gelsomino, F., Wong, M. K., Morse, M. A., Cutsem, E. V., Hendlisz, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.554 · Cited by 56 · see citing works

Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC)

Grimm, M., Schmidinger, M., Martinez, I. D., Schinzari, G., Esteban, E., Schmitz, M., Schumacher, U., Baretton, G. B., Barthélémy, P., Melichar, B., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.051 · Cited by 55 · see citing works

The Tumor Microenvironment at a Turning Point—Knowledge Gained Over the Last Decade, and Challenges and Opportunities Ahead: A White Paper from the NCI TME Network

DeClerck, Y. A., Pienta, K. J., Woodhouse, E. C., Singer, D. S., & Mohla, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1336 · Cited by 44 · see citing works

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.

Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, M. K., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4040 · Cited by 43 · see citing works

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer

Winer, A., Ghatalia, P., Bubes, N., Anari, F. M., Varshavsky, A., Kasireddy, V., Liu, Y., & El‐Deiry, W. S. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0686 · Cited by 40 · see citing works

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.

Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H., Gelsomino, F., Aglietta, M., Morse, M. A., Cutsem, E. V., McDermott, R., Hill, A. G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.635 · Cited by 38 · see citing works

Comprehensive Paired Tumor/Germline Testing for Lynch Syndrome: Bringing Resolution to the Diagnostic Process

Salvador, M. U., Truelson, M. R. F., Mason, C. L., Souders, B., LaDuca, H., Dougall, B., Black, M. H., Fulk, K., Profato, J., Gutierrez, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00696 · Cited by 35 · see citing works

Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors.

Segal, N. H., Wainberg, Z. A., Overman, M. J., Ascierto, P. A., Arkenau, H., Butler, M. O., Eder, J. P., Keilholz, U., Kim, D., Cunningham, D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.670 · Cited by 32 · see citing works

Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer

Cohen, R., Jonchère, V., de la Fouchardière, C., Ratovomanana, T., Letourneur, Q., Ayadi, M., Armenoult, L., Buisson, A., Sarabi, M., Pellat, A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001903 · Cited by 30 · see citing works

Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab

Das, S., Allen, A., & Berlin, J. D. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.006 · Cited by 26 · see citing works

Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas

On behalf of investigators from the Melbourne Collaborative Cohort Study and the Australasian Colorectal Cancer Family Registry Cohort, Clendenning, M., Huang, A., Jayasekara, H., Lorans, M., Preston, S., O’Callaghan, N., Pope, B. J., Macrae, F., Winship, I., et al. (2017) · Familial Cancer · doi:10.1007/s10689-017-0013-y · Cited by 25 · see citing works

Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.

Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, K. Y. M., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.58 · Cited by 19 · see citing works

Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8

Laurent‐Puig, P., Marisa, L., Ayadi, M., Blum, Y., Balogoun, R., Pilati, C., Malicot, K. L., Lepage, C., Emile, J., Salazar, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy269.058 · Cited by 18 · see citing works

Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.

Morris, V. K., Lam, M. S., Wang, X., Overman, M. J., Johnson, B., Kee, B. K., Wolff, R. A., Dasari, A. N., Zorrilla, I. R., Tam, A. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.79 · Cited by 17 · see citing works

396O Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study

André, T., Amonkar, M. M., Norquist, J. M., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., García‐Carbonero, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.507 · Cited by 10 · see citing works

Salvage combination ipilimumab and nivolumab after failure of prior checkpoint inhibitor therapy in patients with advanced melanoma.

Gaughan, E. M., Petroni, G. R., Grosh, W. W., & Slingluff, C. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e21009 · Cited by 6 · see citing works

Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment

Lisi, L., Lacal, P. M., Martire, M., Navarra, P., & Graziani, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105997 · Cited by 105 · see citing works

Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164

Le, D. T., Diaz, L. A., Kim, T. W., Cutsem, E. V., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B. H., Kavan, P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.016 · Cited by 100 · see citing works

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers

Amodio, V., Mauri, G., Reilly, N. M., Bianchi, A. S., Siena, S., Bardelli, A., & Germano, G. (2021) · Cancers · doi:10.3390/cancers13112638 · Cited by 67 · see citing works

Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022

André, T., Cohen, R., & Salem, M. E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349557 · Cited by 63 · see citing works

Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability

Ratovomanana, T., Nicolle, R., Cohen, R., Diehl, A., Siret, A., Letourneur, Q., Buhard, O., Perrier, A., Guillerm, E., Coulet, F., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.010 · Cited by 59 · see citing works

Colorectal Cancer Immunotherapy: State of the Art and Future Directions

Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39 · see citing works

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works

Exploring the Role of the Gut Microbiota in Modulating Colorectal Cancer Immunity

Shakhpazyan, N. K., Михалева, Л. М., Bedzhanyan, A. L., Владиславовна, Г. З., Mikhalev, A. I., Midiber, K. Y., Pechnikova, V. V., & Biryukov, A. E. (2024) · Cells · doi:10.3390/cells13171437 · Cited by 36 · see citing works

Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?

Hu, L., Lan, H., Huang, D., Li, X., & Jin, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769305 · Cited by 34 · see citing works

A synopsis of modern - day colorectal cancer: Where we stand

Ranasinghe, R., Mathai, M. L., & Zulli, A. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188699 · Cited by 34 · see citing works

A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery

Shadbad, M. A., Asadzadeh, Z., Derakhshani, A., Hosseinkhani, N., Mokhtarzadeh, A., Baghbanzadeh, A., Hajiasgharzadeh, K., Brunetti, O., Argentiero, A., Racanelli, V., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112213 · Cited by 29 · see citing works

Comprehensive Landscape of RRM2 with Immune Infiltration in Pan-Cancer

Zhou, Z., Song, Q., Yang, Y., Wang, L., & Wu, Z. (2022) · Cancers · doi:10.3390/cancers14122938 · Cited by 26 · see citing works

Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers

Capuozzo, M., Picone, C., Sabbatino, F., Santorsola, M., Caraglia, F., Iervolino, D., Sirica, R., Gualillo, O., Mauro, G. D., Castiello, R., et al. (2025) · Cancers · doi:10.3390/cancers17213438 · Cited by 23 · see citing works

Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives

Personeni, N., Smiroldo, V., Giunta, E. F., Prete, M. G., Rimassa, L., Bregni, G., & Sclafani, F. (2021) · Cancers · doi:10.3390/cancers13184506 · Cited by 19 · see citing works

Integrated Profiling Identifies PLOD3 as a Potential Prognostic and Immunotherapy Relevant Biomarker in Colorectal Cancer

Shi, J., Bao, M., Wang, W.-F., Wu, X., Li, Y., Changdong, Z., & Liu, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722807 · Cited by 20 · see citing works

KDM1A Facilitates Oncogenic Potential in Colorectal Cancer Progression Through the Activation of AXIN/GSK3β/β‐Catenin Signaling Pathways: Evidence From Integrated Transcriptomics and In Vitro Studies

Natarajan, S. R., Krishnamoorthy, R., Alshuniaber, M. A., Gatasheh, M. K., Rajagopal, P., Veeraraghavan, V. P., Palanisamy, C. P., & Jayaraman, S. (2025) · The Journal of Gene Medicine · doi:10.1002/jgm.70053 · Cited by 16 · see citing works

Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab

Graziani, G., Lisi, L., Tentori, L., & Navarra, P. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_10 · Cited by 15 · see citing works

Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials

Cancanelli, L., Rivano, M., Spazio, L. D., Chiumente, M., Mengato, D., & Messori, A. (2021) · Cureus · doi:10.7759/cureus.19893 · Cited by 13 · see citing works

Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer

Yao, P., Gao, M., Hu, W., Wang, J., Wang, Y., Wang, Q., & Ji, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107209 · Cited by 11 · see citing works

Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair/microsatellite instability: misdiagnosis, pseudoprogression and/or tumor heterogeneity?

Normanno, N., Caridi, V., Fassan, M., Avallone, A., Ciardiello, F., & Pinto, C. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00231 · Cited by 10 · see citing works

Gut Microbiota and Ferroptosis in Colorectal Cancer: A Comprehensive Review of Mechanisms and Therapeutic Strategies to Overcome Immune Checkpoint Resistance

Cai, Y., Zhao, F., & Cheng, X. (2025) · Biomolecules · doi:10.3390/biom15111546 · Cited by 10 · see citing works

Neoantigens and their clinical applications in human gastrointestinal cancers

Eshkiki, Z. S., Agah, S., Tabaeian, S. P., Sedaghat, M., Dana, F., Talebi, A., & Akbari, A. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02776-y · Cited by 10 · see citing works

PD-L1 expression, tumor-infiltrating lymphocytes, and mismatch repair proteins status in digestive neuroendocrine neoplasms: exploring their potential role as theragnostic and prognostic biomarkers

Multone, E., Rosa, S. L., Sempoux, C. L., & Uccella, S. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03825-5 · Cited by 7 · see citing works

Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation

Cohen, R., Raeisi, M., Chibaudel, B., Yoshino, T., Shi, Q., Zalcberg, J. R., Adams, R., Cremolini, C., Grothey, A. A., Mayer, R. J., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113537 · Cited by 7 · see citing works

A Review of 10-Year Survivability of Immunotherapy in the Management of Colon Cancer

Okoye, C., Tran, M., Soladoye, E., Akahara, D. E., Emeasoba, C. M., Ojinna, B. T., Kelechi, A. E., Obadare, O. O., Diala, C. S., Salaudeen, B. H., et al. (2023) · Cureus · doi:10.7759/cureus.43189 · Cited by 6 · see citing works

Lynch Syndrome-Associated Glioblastoma Treated With Concomitant Chemoradiotherapy and Immune Checkpoint Inhibitors: Case Report and Review of Literature

Nakase, K., Matsuda, R., Sasaki, S., & Nakagawa, I. (2024) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2023.0042 · Cited by 5 · see citing works

Real-world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: the COALA project

Hitchen, N., Wong, H., Wong, R., Shapiro, J., Burge, M., Nott, L., Lee, B. R., Lim, S. H.-S., Wong, S. F., Caird, S., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100178 · Cited by 3 · see citing works

Breaching the immune-cold barrier in pMMR/MSS metastatic colorectal cancer: emerging strategies beyond standard care

Kang, W., Zhang, Z., Li, W., Zhang, Q., Li, N., Jiang, Y., Zhang, J., & He, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773002 · Cited by 3 · see citing works

Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers

Cho, M. T., Beechinor, R. J., Gholami, S., & Grothey, A. F. (2021) · Current Colorectal Cancer Reports · doi:10.1007/s11888-021-00466-7 · Cited by 3 · see citing works

Immune checkpoint inhibitors in colorectal cancer: dream and reality

André, T., & Cohen, R. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00375-7 · Cited by 3 · see citing works

Development of novel models for predicting mismatch repair protein deficiency and relevant disease-free survival in colorectal cancer patients

Xu, Y., Li, Y., Zhu, Z., Yang, J., Tan, Y., Wang, Y., & Xu, X. (2022) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04150-6 · Cited by 2 · see citing works

Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient

Torchiaro, E., Petti, C., Arena, S., Sassi, F. P., Migliardi, G., Mellano, A., Porporato, R., Basiricò, M., Gammaitoni, L., Berrino, E., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1130852 · Cited by 2 · see citing works

Dendritic cell membrane-based DCsLipo@MnO2@siCTLA4@PD-1α nanomedicine for the treatment of Lynch syndrome-related colorectal cancer

Zhong, W., Wang, P., Wang, J., Zhu, Y., Chen, L., Qian, Y., Huang, X., & Ye, K. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102045 · Cited by 2 · see citing works

Pharmacotherapy for unresectable metastatic colorectal cancer

Rogers, J. E., & Dasari, A. N. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1982895 · Cited by 2 · see citing works

Updates in BRAF V600E-Mutated Metastatic Colorectal Cancer

Scott, B. (2024) · EMJ Oncology · doi:10.33590/emjoncol/jdxk9403 · Cited by 1 · see citing works

Prognostic Features and Potential for Immune Therapy in Metastatic Mismatch Repair‐Deficient Colorectal Cancer: A Retrospective Analysis of a Large Consecutive Population‐Based Patient Series

Wirta, E., Elomaa, H., Mecklin, J., Seppälä, T. T., Hyöty, M. K., Böhm, J., Ahtiainen, M., & Väyrynen, J. P. (2025) · Cancer Medicine · doi:10.1002/cam4.70555 · Cited by 1 · see citing works

Rethinking Immune Checkpoint Inhibition in Cancer

Bakács, T., & Anderson, C. C. (2026) · Scandinavian Journal of Immunology · doi:10.1111/sji.70106 · Cited by 1 · see citing works

Immune microenvironment evolution across the serrated neoplasia pathway and its relevance to immunotherapy

Jin, C., Liu, H., Wu, Z., Hu, Y., Cui, Y., Guo, R., & Li, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1830436 · Cited by 1 · see citing works

Importance of Early Next-Generation Sequencing in Microsatellite Unstable Colon Cancer With a High Tumor Mutation Burden

Sethi, A. K., & Raj, M. S. (2022) · Cureus · doi:10.7759/cureus.22894 · Cited by 1 · see citing works

Locally advanced rectal cancer patients with mismatch repair protein deficiency can obtain better pathological response after regional chemoembolization

Gao, Y., Xiao, H., Meng, W., Liao, J., Chen, Q., Zhao, G., Li, C., & Bai, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1131690 · Cited by 1 · see citing works

Updates on DNA Repair Gene Deficiency in Colorectal Cancer (dMMR)

Sevá‐Pereira, G., Coy, C. S. R., & Martinez, C. A. R. (2025) · Journal of Coloproctology · doi:10.1055/s-0045-1805009 · Cited by 1 · see citing works

Pembrolizumab beim MSI-h-mCRC

Schalhorn, A. (2021) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-021-8780-x · Cited by 1 · see citing works

Une charge mutationnelle élevée est-elle prédictive de l’efficacité des inhibiteurs de checkpoints immunitaires en termes de survie globale en pan-cancer ?

André, T., & Cohen, R. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.04.001

Beeindruckende Effektivität der primären PD-1-Hemmung

Schalhorn, A. (2023) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-022-9814-8

Beeindruckende Effektivität der primären PD-1-Hemmung

Schalhorn, A. (2023) · Gastro-News · doi:10.1007/s15036-023-3232-0

Turning self cancer cells into nonself by viral xenogenization to ignite response in immune checkpoint inhibitors nonresponders

Bakács, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29164-7.00001-7

Diagnostic Challenges of Tumor Tissue and Circulating Microsatellite Status Assessment in Metastatic Colorectal Cancer and Their Impact on Access to Immunotherapy: A Real-World Retrospective Study

Chibaudel, B., Dainese, L., Carola, É., Goyer, P., Richa, H., Saget, A., Oberlin, O., Marijon, H., Perez‐Staub, N., de Gramont, A., et al. (2026) · Cancers · doi:10.3390/cancers18122006

Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency

Cohen, R., Pellat, A., Boussion, H., Svrcek, M., López‐Trabada, D., Trouilloud, I., Afchain, P., & André, T. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.09.004 · Cited by 20 · see citing works

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability

Borelli, B., Antoniotti, C., Carullo, M., Germani, M. M., Conca, V., & Masi, G. (2022) · Cancers · doi:10.3390/cancers14204974 · Cited by 62 · see citing works

Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?

Matteucci, L., Bittoni, A., Gallo, G., Ridolfi, L., & Passardi, A. (2023) · Cancers · doi:10.3390/cancers15215189 · Cited by 15 · see citing works

Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma

Román, M. S., Torres-Jiménez, J., Pozas, J., Esteban-Villarrubia, J., Albarrán, V., Ballesteros, P. Á., Chamorro-Pérez, J., Rodriguez, D. I. R., Orejana, I., Martínez-Delfrade, Í., et al. (2023) · Cancers · doi:10.3390/cancers15030863 · Cited by 28 · see citing works

Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022

André, T., Cohen, R., & Salem, M. E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349557 · Cited by 63 · see citing works